[ XXXX : pharmacological and clinical properties of the first member of a new anxiolytic drug family].

@entity1 @entity8 @entity308 @entity5633 @entity4697 @entity167 @entity344 @entity1245 @entity148 @entity1575 @entity10 @entity734
@entity5633 is a new anxiolytic agent with an original chemical structure. Its activity in doses of 15 to 30 mg per day has been demonstrated in @entity1 presenting with manifestations of generalized @entity148 . Its mode of action is still imperfectly known; in animals, it influences several neuromediator systems but does not act on @entity1245 receptors. Its main pharmacokinetic features are: complete absorption when given orally, short half-life (4 to 8 h), reduced plasma clearance in @entity1 with @entity1575 or @entity8 and no major interaction with most of the other psychotropic drugs. Controlled clinical studies have provided evidence of its anxiolytic properties; against @entity148 symptoms @entity5633 has proved more effective than placebo and as effective as several reference @entity1245 derivatives, with a lesser incidence of sedative effects. However, it is not effective in the treatment of @entity1245 withdrawal. @entity344 and moderate @entity10 have been reported in less than 10 p. 100 of the @entity1 treated. Administered acutely, @entity5633 does not seem to alter cognitive mechanisms. Unlike @entity1245 , it does not potentiate the effects of @entity167 and does not lead to @entity734 . Its usefulness in @entity4697 , @entity308 states and obsessional symptoms remains to be determined.
